文献速递间质性肺疾病

外显子组测序揭示罕见遗传变异在肺纤维化中的作用

An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2017-01-01

该病例对照外显子组关联研究纳入262例肺纤维化患者和4141例欧洲 ancestry 对照,在18668个蛋白编码基因中搜索罕见有害变异富集。研究发现TERT、RTEL1和PARN三个端粒相关基因达到研究-wide显著富集,且11.3%的散发性IPF患者携带这三个基因中一个的合格变异,而对照组仅0.3%,支持端粒功能障碍参与IPF发病机制。

要点

  • TERT、RTEL1和PARN罕见有害变异与肺纤维化显著相关,支持端粒功能障碍参与IPF发病。
  • 散发性IPF患者中11.3%携带TERT、RTEL1或PARN合格变异,对照组仅0.3%。
  • 多数病例无家族史,提示这些基因变异也贡献于散发性IPF。

核心结论

  • TERT、RTEL1和PARN三个端粒相关基因是散发性IPF的显著贡献因素,支持端粒功能障碍参与IPF发病机制。

研究设计与样本

  • 病例对照外显子组-wide collapsing分析,纳入262例肺纤维化患者和4141例欧洲 ancestry 对照。
  • 262例中81.3%临床分类为IPF,11.5%为继发于自身免疫疾病的UIP,7.2%为纤维化NSIP;87%无家族史。

主要发现

  • 在18668个蛋白编码基因中,TERT、RTEL1和PARN的合格变异显示研究-wide显著病例富集(P < 4.5 × 10-7)。
  • 超罕见有害非同义变异模型涉及TERT和RTEL1,功能丧失变异模型涉及RTEL1和PARN。
  • 186例散发性IPF亚组分析确认TERT、RTEL1和PARN为研究-wide显著贡献因素。
  • 散发性IPF病例中11.3%携带这三个基因之一的合格变异,对照组携带率为0.3%(OR 47.7,95%CI 21.5-111.6,P = 5.5 × 10-22)。

临床怎么用

  • 对肺纤维化患者,尤其散发性IPF,可考虑TERT、RTEL1和PARN罕见有害变异的遗传评估。
  • 端粒相关基因变异结果有助于理解IPF遗传架构,支持端粒功能障碍作为发病机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is an increasingly recognized, often fatal lung disease of unknown etiology. OBJECTIVES: The aim of this study was to use whole-exome sequencing to improve understanding of the genetic architecture of pulmonary fibrosis. METHODS: We performed a case-control exome-wide collapsing analysis including 262 unrelated individuals with pulmonary fibrosis clinically classified as IPF according to American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines (81.3%), usual interstitial pneumonia secondary to autoimmune conditions (11.5%), or fibrosing nonspecific interstitial pneumonia (7.2%). The majority (87%) of case subjects reported no family history of pulmonary fibrosis. MEASUREMENTS AND MAIN RESULTS: We searched 18,668 protein-coding genes for an excess of rare deleterious genetic variation using whole-exome sequence data from 262 case subjects with pulmonary fibrosis and 4,141 control subjects drawn from among a set of individuals of European ancestry. Comparing genetic variation across 18,668 protein-coding genes, we found a study-wide significant (P < 4.5 × 10-7) case enrichment of qualifying variants in TERT, RTEL1, and PARN. A model qualifying ultrarare, deleterious, nonsynonymous variants implicated TERT and RTEL1, and a model specifically qualifying loss-of-function variants implicated RTEL1 and PARN. A subanalysis of 186 case subjects with sporadic IPF confirmed TERT, RTEL1, and PARN as study-wide significant contributors to sporadic IPF. Collectively, 11.3% of case subjects with sporadic IPF carried a qualifying variant in one of these three genes compared with the 0.3% carrier rate observed among control subjects (odds ratio, 47.7; 95% confidence interval, 21.5-111.6; P = 5.5 × 10-22). CONCLUSIONS: We identified TERT, RTEL1, and PARN-three telomere-related genes previously implicated in familial pulmonary fibrosis-as significant contributors to sporadic IPF. These results support the idea that telomere dysfunction is involved in IPF pathogenesis.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Petrovski S, Todd JL, Durheim MT, et al. An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017. PMID: 28099038. doi:10.1164/rccm.201610-2088OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。